Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference

Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Jan. 13, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused…

Continue Reading
Aurora Spine Announces Attendance at J.P. Morgan Healthcare

Aurora Spine Announces Attendance at J.P. Morgan Healthcare

CARLSBAD, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”)…

Continue Reading